



CSL Limited
ABN: 99 051 588 348
655 Elizabeth Street
Melbourne
Victoria 3000 Australia
T +613 9389 1911
F +613 9389 1434
[CSL.com](https://www.csl.com)

ASX Announcement

For immediate release

11 April 2024

CSL Australia Investor Site Tour Presentations

The presentation materials to be used for an Investor Site Tour being conducted by CSL (ASX:CSL; USOTC:CSLLY) in Melbourne today are attached for the information of investors.

Authorised By

Fiona Mead
Company Secretary

For further information, please contact:

Investors:

Bernard Ronchi
Director, Investor Relations
CSL Limited
P: +61 3 9389 3470
E: bernard.ronchi@csl.com.au

Stephen McKeon
Director, Investor Relations
CSL Limited
P: 61 402 231 696
E: stephen.mckeon@csl.com.au

Media:

Bernadette Murdoch
Communications
CSL Limited
P: +61 449 950 7451
E: Bernadette.murdoch@csl.com.au

A woman with blonde hair, wearing clear safety glasses and a white lab coat over a green shirt, is shown in profile, looking down at a piece of laboratory equipment. The background is a bright, out-of-focus laboratory setting.

CSL

Investor Tour
CSL Behring &
CSL Seqirus

April 2024

Legal Notice

IMPORTANT NOTICE AND DISCLAIMER

This presentation contains summary information about CSL Limited (ACN 051 588 348) and its related bodies corporate (together, **CSL**) and CSL's activities as at the date of this presentation. It is information given in summary form only and does not purport to be complete. It should be read in conjunction with CSL's other periodic corporate reports and continuous disclosure announcements filed with the Australian Securities Exchange (**ASX**), available at www.asx.com.au. This presentation is for information purposes only and is not a prospectus or product disclosure statement, financial product or investment advice or a recommendation to acquire CSL shares or other securities.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of CSL or its directors, employees or agents, nor any other person, accepts liability for any loss arising from the use of this presentation or its contents or otherwise arising in connection with it, including, without limitation, any liability from fault or negligence on the part of CSL or its directors, employees, contractors or agents.

This presentation contains forward-looking statements in relation to CSL, including statements regarding CSL's intent, belief, goals, objectives, initiatives, commitments or current expectations with respect to CSL's business and operations, market conditions, results of operations and financial conditions, products in research, risk management practices, climate change and other environmental and energy transition scenarios. Forward-looking statements can generally be identified by the use of words such as "forecast", "estimate", "plan", "will", "anticipate", "may", "believe", "should", "expect", "project", "intend", "outlook", "target", "assume" and "guidance" and other similar expressions.

The forward-looking statements are based on CSL's good faith assumptions as to the financial, market, risk, regulatory and other relevant environments that will exist and affect CSL's business and operations in the future. CSL does not give any assurance that the assumptions will prove to be correct. The forward-looking statements involve known and unknown risks, uncertainties and assumptions and other important factors, many of which are beyond the control of CSL, that could cause the actual results, performances or achievements of CSL to be materially different to future results, performances or achievements expressed or implied by the statements. Factors that could cause actual results to differ materially include: the success of research and development activities, decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; competitive developments affecting our products; the ability to successfully market new and existing products; difficulties or delays in manufacturing; trade buying patterns and fluctuations in interest and currency exchange rates; legislation or regulations that affect product production, distribution, pricing, reimbursement, access or tax; acquisitions or divestitures; research collaborations; litigation or government investigations, advances in environmental protection processes, uncertainty and disruption caused by the COVID-19 pandemic and CSL's ability to protect its patents and other intellectual property.

Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as at the date of the presentation. Except as required by applicable laws or regulations, CSL does not undertake any obligation to publicly update or revise any of the forward-looking statements or to advise of any change in assumptions on which any such statement is based.

TRADEMARKS

Except where otherwise noted, brand names designated by a TM or ® throughout this presentation are trademarks either owned by and/or licensed to CSL.



Acknowledgement of Country

CSL acknowledges Traditional Owners of Country throughout Australia and recognises their continuing connection to lands, waters and communities. We pay our respects to all Aboriginal and Torres Strait Islander cultures; and to Elders past and present.

Artwork by Simone Thomson as featured in CSL's Reflect Reconciliation Action Plan

The CSL logo is a red square with the letters 'CSL' in white, bold, sans-serif font. The background of the entire slide is a blurred photograph of a pharmaceutical manufacturing facility, showing various pieces of machinery, pipes, and containers in shades of blue, yellow, and white.

CSL

CSL Behring Broadmeadows

Investor Tour

April 2024

Mike Deem
Head Of Operations
CSL Behring

Andrew Hodder
Manufacturing & Site Head
CSL Behring Australia

Visitor Safety Procedures

While you are in the facility you will be escorted by CSL Behring personnel

In the event of an emergency follow the instructions provided by your guide

Alert Tone – “BEEP-BEEP-BEEP”

- Standby and await instructions of wardens

Evacuate Tone – “WHOOOP-WHOOP-WHOOP”

- Evacuate as instructed by your wardens



Site Safety Rules



Be fit for work and free from drugs and alcohol



Know what to do in an emergency



Hold handrails when using stairs



Wear safety equipment required by procedures and signage



Use designated pedestrian crossings, footpaths and walkways



Drive safely and within the speed limits



Ensure contractors working on site hold up the same standards expected of CSL employees



Don't use mobile phones while walking on pedestrian crossings, walkways on roads, or walking through carparks



Maintain three metre distance from forklifts where physical separation cannot be achieved



Check energised equipment and lines are correctly isolated, tagged and locked before commencing work



Familiarise yourself with the hazards and chemicals involved in your work and follow safety procedures

Who we are

CSL is a global biotechnology leader that develops and delivers innovative medicines that save lives, protects public health and helps people with life-threatening medical conditions live full lives.



Cheryl Blackwell Johnson
Living with HAE

Leading global biotech company

We are a global biotechnology leader that develops and delivers innovative medicines that save lives, protects public health and helps people with life-threatening medical conditions live full lives

 **40+** Countries of operations around the world

US\$13.3bn in annual revenue (FY23)

9 Manufacturing sites across 6 countries



 **32,000+** Employees around the world¹

 **US\$5.1bn** R&D investment in the last 5 financial years

 **2,000+** R&D employees¹

 **340+** Plasma collection centres primarily in the US¹



CSL group operating structure

	CSL Behring Global Biotherapeutics Leader	CSL Seqirus Global Influenza Vaccines Leader	CSL Vifor Global Specialty Pharma Leader
Overview	<ul style="list-style-type: none"> • One of the world's largest collectors of plasma and providers of plasma therapies • Develops and delivers high-quality medicines that treat rare and serious diseases • Manufactures, markets and develops plasma and recombinant therapies • Early-stage research on plasma and non-plasma therapies (excluding influenza) • Receives license and royalty income from commercialisation of IP • Focuses on five key therapeutic areas¹ 	<ul style="list-style-type: none"> • One of the largest influenza vaccine companies in the world by revenue • Formed in 2015 through the combination of bioCSL and Novartis influenza vaccines business • In Australia and New Zealand, a leading provider of in-licensed vaccines and specialty pharmaceuticals • Supplier to the Australian Government for a range of products, including antivenoms and Q fever vaccine 	<ul style="list-style-type: none"> • Global specialty pharmaceuticals business that is a leader in iron therapies, dialysis, nephrology and rare diseases • Specialises in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision healthcare • Joint company, Vifor Fresenius Medical Care Renal Pharma (VFMCRP) with Fresenius Medical Care, a global leader in dialysis
% of Revenue²	70%	15%	15%
Global Footprint	<ul style="list-style-type: none"> • Operations in over 40 countries • Markets in over 100 countries • 6 manufacturing sites in 5 countries 	<ul style="list-style-type: none"> • Operations in over 15 countries • 3 manufacturing sites in 3 countries • Research & production facilities and manufacturing plants across North America, Europe and Australia 	<ul style="list-style-type: none"> • Markets in over 100 countries • Broad global network of affiliates and partners • Certain final stage production processes are outsourced to contract manufacturing organisations

Source: Company filings.

1. Five key therapeutic areas are immunology, hematology, respiratory, cardiovascular & metabolic and transplant.

2. Based on FY23 revenue.

CSL Behring: Driving sustainable, profitable growth

Working together from Donor to Patient



CSL Behring – Global manufacturing presence



Bern, Switzerland

- **Core products:** immunoglobulins & albumin
- **Specialty products:** anti-D-hyperimmune



Broadmeadows, Australia

- **Core products:** immunoglobulins & albumin
- **Specialty products:** coagulation factors, critical care
- **Toll plasma services** for Australia, New Zealand, Hong Kong, Malaysia & Taiwan



Marburg, Germany

- **Core products:** human albumin, coagulation factors, critical care
- **Specialty products:** hyperimmunes



Kankakee, Illinois, US

- **Core products:** albumin, fractionation for intermediate pastes
- **Specialty products:** alpha1-proteinase inhibitor




Wuhan, China

- **Core products:** albumin, immunoglobulins

CapEx investments are providing capacity for growth

CSL expects CapEx investment needs to reduce as major projects are now coming online



From donor to patient: Manufacturing plasma biotherapies



PLASMA DONATION

The process starts with plasma donors who play a vital role



TRANSPORTATION

Frozen plasma and plasma pastes are transported to site




COLD STORAGE FREEZER

Plasma and pastes are held in cold storage until needed




FRACTIONATION

Separation of whole plasma into component parts



BULK MANUFACTURING

Reconstitution and filtration to manufacture biotherapies



FILLING

Formulation and filling of bulk product into vials



VISUAL INSPECTION

Safety and quality checks of every vial



QUALITY CONTROL / TESTING

Testing of finished products and all manufacturing consumables



PACKING

Labelling, boxing and packing all products ready for distribution to patients



HOSPITALS & PATIENTS

Finished products are distributed to hospitals and direct to patients around the world


WELCOME TO BROADMEADOWS





CSL BEHRING BROADMEADOWS

- Site opened 1994
- Commercial facilities for production of PRIVIGEN®, AlbuRx® and Hizentra®
- 1,200+ employees
- Domestic plasma fractionation for Australia, New Zealand, Hong Kong, Taiwan, Malaysia
- Recombinant manufacturing facility for clinical trial production



Promising **FUTURES**

OUR WORKFORCE



1,268

EMPLOYEES

92%

FULL TIME HOURS

89%

PERMANENT EMPLOYEES

40 years

AVERAGE AGE

1 in 5

EMPLOYEES ARE PEOPLE MANAGERS

38%

EMPLOYEES ARE FEMALE

10,368 years

OF COMBINED SERVICE

1 in 10

EMPLOYEES ARE OVER 55 YEARS OLD

29.5%

OF PEOPLE MANAGERS ARE FEMALE

81%

EMPLOYEE ENGAGEMENT INDEX SCORE

8 years

AVERAGE TENURE

90%

OF EMPLOYEES IN STEM

Our Customers

GLOBAL COMMERCIAL SUPPLY

CSL Behring

Plasma supplied through CSL Plasma sourced in the USA

CSL Seqirus

Future expansion will support Filling and Packing operations for CSL Seqirus Tullamarine site

REGIONAL DOMESTIC SUPPLY

Contract Domestic Manufacturing supply agreements:

- National Blood Authority (Australia)
- NZ Blood (New Zealand)
- Taiwan Blood Services Foundation (Taiwan)
- Pusat Darah Negara (Malaysia)
- Hong Kong Red Cross Blood Transfusion Service

CSL BEHRING BROADMEADOWS

1. Haemophilia and Specialty Products Facility (Domestic/Contract)
2. Turner Facility (PRIVIGEN®, Hizentra®)
3. Facility A (AlbuRx®, Alburex®)
4. Facility F (Base Fractionation)
5. Biotech Manufacturing Facility (Recombinant)



Product Portfolio

CSL Behring Broadmeadows

KEY
Current portfolio
Future filling capacity

Critical Care

Albumin solutions

Human Albumin Behring®
Alburex®, AlbuRx®, Albumex®, Albuminar®

Inhibitors

Beriner® P, Haegarda®, Beriner SC®
Kybernin® P

Other trauma therapies

Beriplex® P/N, Coaplex, Kcentra®
RiaSTAP® Haemocompletan® P
Thrombotrol®
Prothrombinex®

Wound Healing

Beriplast® P Combi-Set
Fibrogammin®, Corifact®, Cluvot®
Fibrinogen active substance

Pulmonology

Zemaira®
Respreeza®

Immunology

Polyvalent immunoglobulins

Privigen®, Privigen® AU
Hizentra®

Carimune® NF
Sandoglobulin®
Intragam®
Evogam®
Hyperimmunes
Rhopylac®, Rhesogam
CytoGam®
Beriglobin® P
Berirab® P
Hepatitis B IG P Behring®
Tetagam® P

Domestic Hyperimmunes produced at Broadmeadows

Cytomegalovirus Immunoglobulin-VF
Hepatitis B Immunoglobulin-VF
Rh(D) Immunoglobulin (Anti-D)
Tetanus Immunoglobulin-VF IM
Tetanus Immunoglobulin-VF IV
Zoster Immunoglobulin-VF
Normal Immunoglobulin-VF

Coagulation

Plasma-derived factor II

Human Thrombin active substance
Recombinant factor VIII
Afstyla®

Recombinant factor IX

Idelvion®

Factor VIII:C/von Willebrand factor

Haemate® P, Humate® P, Voncento®, Biostate®

Plasma-derived factor VIII

Beriate® P, Biostate®
Plasma-derived factors X
Factor X P Behring®
Gene therapy - Hemgenix®

CSL Seqirus

Afluria®
Flucelvax® Tetra
PNS (Antivenoms)

MORE THAN A DECADE OF SUSTAINED GROWTH AND ALMOST A\$2B IN CAPITAL INVESTMENT

2013



Turner
PRIVIGEN
Facility

2014



Biotechnology
Manufacturing
Facility

2017



Facility A
AlbuRx

2022



Facility F Base
Fractionation
and Logistics
Hub

FUTURE

Filling capacity
expansion

Ig yield

Albumin
capacity
expansion

Sustainability Initiatives at Broadmeadows

CSL target: 40% reduction of Scope 1&2 emissions by 2030 against a baseline of average emissions across FY19-21

- Power Purchase Agreement for Australian renewable electricity will make a substantial contribution to achieving target
- Broadmeadows is the largest proportion of CSL's electricity use and emissions in Australia
- Agreement starts in January 2025
- Energy efficiency projects focused on steam generated from natural gas to reduce Scope 1 emissions are being investigated



Local sustainability initiatives

- On site ethanol recovery and recycling for reuse in manufacturing processes
- Evaluating waste reduction involving site audits and a workshop with waste service providers to set priority projects for action

20
in
30

**CSL BEHRING BROADMEADOWS
FUTURE VISION**

**20 million+ vials
in 2030**

Our Vision

A world-class facility and network partner, reliably delivering for Our Patients.

Our Mission

We deliver live-saving therapies for Our Patients, collaborating globally to continuously improve production capacity. Our people are committed to delivering excellence, working with agility and innovating to strengthen our business today and deliver for our bright future.

CSL Behring



CSL

CSL Seqirus A Global Network

Driven by Our Promise to
Protect Public Health


April 2024

Chris Larkins
SVP, Global Operations

Jonah Smith
VP Program Lead – Project Banksia

CSL Seqirus growth linked directly to differentiation strategy and core capabilities

CSL Seqirus historic growth



Cornerstones for Success



Real World
Evidence
Platform



Differentiation
Strategy




Focus on
Innovation



Scaled
Manufacturing
Platforms


CSL Seqirus's focus within its 4 strategic pillars drives its near and long-term success

1. CONTINUED GROWTH IN INFLUENZA



Opportunities in both new and existing markets to increase our global footprint

2. BROADEN OUR PANDEMIC BUSINESS




Multi-pathogen pandemic capability

3. GROW BEYOND INFLUENZA




Leverage core competence of respiratory vaccines

4. INVEST IN SCALABLE MANUFACTURING TECHNOLOGY




Common technologies and yield investments to underpin our growth



In influenza, Seqirus will grow the market through differentiation despite lower immunisation rates

Historic Trend (US)

Influenza Vaccine Doses Distributed in the United States, By Season



Source: www.cdc.gov

Millions of Doses

Expectations

- Influenza still has significant unmet need, particularly in paediatric and older adult populations
- Immunisation rates will return over time
- Annualisation of COVID-19 boosters will reduce vaccine fatigue
- CSL Seqirus growth will outpace the market through differentiation and advocacy efforts

CSL Seqirus focused on continuous innovation to reduce the burden of influenza

Undifferentiated

TIVe



QIVe



Differentiated

QIVc



aTIV
aQIV



aH5N1



- Development Status:
- QIVc: 6-month+ age extension
 - aQIV: Advanced Real-World Evidence

Multiple Differentiators

aH5N1c



aQIVc

sa-mRNA

- Development Status:
- aQIVc: Phase III
 - sa-mRNA flu: Phase I


Technologies will be complementary

Cell will remain basis of rapid pandemic response for Flu

CELL-BASED VACCINE



MF59 ADJUVANT



SELF-AMPLIFYING mRNA VACCINE



sa-mRNA technology differentiates

CSL Seqirus COVID-19 vaccine candidate

Differentiators of sa-mRNA Technology

- 1 Superior response to Omicron strain as a booster in adults vs. approved booster (Phase III)[^]
- 2 Lower dose of mRNA
- 3 Duration of protection up to 12 months

[^] Links to online publications:

<https://www.medrxiv.org/content/10.1101/2023.07.13.23292597v1.full.pdf>

<https://ir.arcturusrx.com/news-releases/news-release-details/study-shows-novel-sa-mrna-vaccines-offer-robust-broad-enduring>

Accelerating to market

- Licensing and collaboration agreement with Arcturus Therapeutics Inc.
- Finalising clinical programs
- Studying emerging variants
- Regulatory submissions

Global Launches Anticipated in 2024 - 2026



Japan
(via Meiji Seika)



EU



UK



US

CSL Seqirus – Global manufacturing presence



Holly Springs NC, US

The world's largest cell-based influenza vaccine manufacturing facility

- First and only site recognized by the U.S. Government with pandemic-ready designation.
- Recent expansion works include new formulation suites and expanded fill and finish capacity



Liverpool, UK

The U.K.'s only injectable influenza vaccine manufacturing facility

- Includes proprietary adjuvant, MF59® manufacturing and high-speed fill and finish line
- Plays an important role in pandemic preparedness and response for the U.K. and other countries in Europe.



Parkville, Australia

Australia's first influenza vaccine manufacturer

- Manufacture of products of national significance, including antivenoms and the Q fever vaccine.
- Produces seasonal and pandemic vaccines for Australia and worldwide.
- Develops candidate vaccine viruses for the World Health Organisation



sa-mRNA CTM, NC, US

New sa-mRNA clinical trial material (CTM) manufacturing facility located within Holly Springs

- Flu Vaccine Clinical Trial Material manufacturing will occur in CSL Seqirus' Vaccine Pilot Plant (VPP) and Small-Scale Filling (SSF) facility at Holly Springs
- SSF operationally setup for H5N1 and H2N3




Waltham, MA, US

State-of-the-Art Vaccine Research and Development Facility

- Pre-clinical manufacturing
- The custom-built Biosafety level 3 laboratory (BSL-3)
- The site will serve as CSL's central hub for current and future vaccine design.

Looking Forward

- CSL Seqirus is well positioned to continue its success in influenza:
 - Capacity development well advanced to support aQIVc launch
- Continuous innovation will enable CSL Seqirus to outpace market growth:
 - aQIVc setting new standard of care
 - sa-mRNA
- sa-mRNA technology will differentiate CSL Seqirus vaccine in COVID-19





CSL SEQIRUS TULLAMARINE

CSL Seqirus Tullamarine

New World Class Flu Cell Culture facility in Australia to meet growing demand and pandemic protection



Project is on target for schedule and budget, with first production in Q1 2026



Cell culture manufacturing



Anti-venom production



Best-in-class sustainability paired with innovative production capabilities

Project Objectives

Australian Biosecurity contract:

- 10-year Biosecurity contract secured with Australian government, commencing in mid-2026
- Secure onshore manufacturing capability for cell-based pandemic influenza response and secure supply of Products of National Significance (PNS).

Seasonal influenza vaccine supply:


- CSL Seqirus Long Range Plan indicates strong seasonal cell-based influenza demand into the future. Tullamarine FCC (Flu Cell Culture) facility (1 line) provides additional global FCC capacity to support that demand.

Pandemic Supply:

- Tullamarine FCC facility provides pandemic capacity to meet future growth in global sales of Pandemic Advance Purchase Agreements (outside of USA).

Critical FCC Milestones:

- Commence production by Jan 2026, registration in Europe by March 2026



3 x 5,000 L FCC bioreactors

Key Deliverables:

- Increase seasonal cell-based influenza capacity by 50% by NH 26/27 Season
- Increase pandemic cell-based influenza capacity by 50% by June 2026
- Secure site licensure and product registrations for Biosecurity contract by June 2026

Project Scope



New CSL Seqirus Tullamarine Site

- Consolidated Drug Substance & Formulated Bulk Manufacture
 - Flu Cell Culture (FCC)
- Products of National Significance (PNS)
 - Supporting QC Laboratories
- Supporting Utilities & Warehousing
 - Site Administration

Plus 3rd Party Logistics

- Raw Material Warehousing



CSL Seqirus Woodend Site

- Venom & Plasma Production and QC Animal Testing




CSL Behring Broadmeadows Site

- Pre-filled Syringe and Vial Fill/Finish
- Raw Materials, Chemistry & Microbiology Quality Control Testing
- Interim Warehousing to support Fill/Finish

Plus 3rd Party Logistics

- Finished Product Warehousing

New CSL Melbourne Site (Elizabeth Street, Melbourne)

- Virus Development (TD Laboratories)
- 



**FUTURE
CSL SEQIRUS
AUSTRALIAN
OPERATIONS**

*A NETWORK
OF SITES TO
DELIVER*

Project Roadmap

Project Delivery (Engineering)

- Design
- Construction
- Automation
- Commissioning and Qualification

Validation, Licensure & Registration

- Process Qualification, Engineering & Media Simulations
- Process Performance Qualification (PPQ)
- Site Licensure & Product Registration

Process C&Q

Engineering Runs
and Media Sims

PPQ

FCC Post-
Tech Transfer
Process
Improvement
Qualification
window

**FCC
Commercial
Manufacture
NH 26/27**

2022

2023

2024

2025

2026


Q1

Q2

Q3


Q4

Construction Progress




- Admin & Labs
- PNS
- Warehouse
- FCC
- Utility Yard

Tullamarine Construction Progress




- Project achieving milestones
- Mechanical & electrical installation complete
- FCC and PNS clean rooms practically complete
- Utilities and Process commissioning underway.
- Certificate of Occupancy received for Admin building
- Full site hand-over to CSL Seqirus on track for April 2024
- On track for process validation in Q4 2024

Digital Manufacturing




Digital Training




Advanced Analytics



Live Viable Cell Density



Sustainability Certification



- On site renewable energy generation
- Electrification of plant to reduce reliance on fossil fuels
- Heat recovery from heat decontaminated liquid waste
- Water recovery and reuse
- Ventilation setback operating modes
- Detailed Waste Management / Circular Economy plans to minimise Construction and Operations Waste
- Reuse of recycled materials in construction

CSL Seqirus Tullamarine on track for:

- ✓ 5 star Green Star rating - all buildings
- ✓ WELL Gold rating - Admin Labs building

